Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01297452 · ClinicalTrials.gov registry record · Phase 1
BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT01297452: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01297452 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 45 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01297452, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to find out the good and bad effects that occur when BKM120 is added to standard chemotherapy with carboplatin and paclitaxel.
Interventions
- DRUG BKM120 days 1 - 21 plus paclitaxel + carboplatin
- DRUG BKM120 (days 1 - 28, ) plus paclitaxel + carboplatin
- DRUG BKM120 (days 1-21) + paclitaxel (day 1) + carboplatin (day 1)
- DRUG BKM120, Paclitaxel + Carboplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2011-02-15 |
| Est. Completion | 2017-03-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01297452
The ClinicalTrials.gov registry entry for NCT01297452 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which BKM120 days 1 - 21 plus paclitaxel + carboplatin is the first listed.
NCT01297452 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01297452 about?
NCT01297452 is a clinical study titled "BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors". The purpose of this study is to find out the good and bad effects that occur when BKM120 is added to standard chemotherapy with carboplatin and paclitaxel.
What is the current status of trial NCT01297452?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2011-02-15. Estimated completion is 2017-03-29.
What interventions are being tested in trial NCT01297452?
The interventions under investigation include: BKM120 days 1 - 21 plus paclitaxel + carboplatin (DRUG), BKM120 (days 1 - 28, ) plus paclitaxel + carboplatin (DRUG), BKM120 (days 1-21) + paclitaxel (day 1) + carboplatin (day 1) (DRUG), BKM120, Paclitaxel + Carboplatin (DRUG).
Who is sponsoring clinical trial NCT01297452?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.